Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Enlivex Therapeutics Ltd. - Ordinary Shares (NQ:ENLV)

0.9699 +0.0699 (+7.77%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,222,147
Open 0.9400
Bid (Size) 0.9600 (100)
Ask (Size) 0.9636 (1,900)
Prev. Close 0.9000
Today's Range 0.9000 - 0.9800
52wk Range 0.8313 - 2.100
Shares Outstanding 18,306,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Enlivex Announces Closing of Previously Announced $212,000,000 Private Placement
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Kartoon Studios Mainframe Studios, Toon Media, and Premium IP Pipeline Drive 2026-2027 Outlook
Via AB Newswire

Performance

YTD
-21.8%
-21.8%
1 Month
-9.4%
-9.4%
3 Month
-7.6%
-7.6%
6 Month
+3.6%
+3.6%
1 Year
-14.9%
-14.9%

More News

Read More
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
News headline image
These stocks are making the most noise in today's session. ↗
Via Chartmill
News headline image
Top movers in Monday's session ↗
Via Chartmill
News headline image
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
ENLV Stock Surges After Pivot To Crypto-Backed Treasury, Names Former Italian PM To Board ↗
Via Stocktwits
Topics ETFs
News headline image
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
What's going on in today's session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Via Benzinga
News headline image
Monday's session: top gainers and losers ↗
Via Chartmill
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
News headline image
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
From Enlivex Therapeutics Ltd
Via GlobeNewswire
News headline image
Enlivex Therapeutics and Foremost Clean Energy Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
News headline image
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
From Enlivex Therapeutics Ltd
Via GlobeNewswire

Frequently Asked Questions

Is Enlivex Therapeutics Ltd. - Ordinary Shares publicly traded?
Yes, Enlivex Therapeutics Ltd. - Ordinary Shares is publicly traded.
What exchange does Enlivex Therapeutics Ltd. - Ordinary Shares trade on?
Enlivex Therapeutics Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Enlivex Therapeutics Ltd. - Ordinary Shares?
The ticker symbol for Enlivex Therapeutics Ltd. - Ordinary Shares is ENLV on the Nasdaq Stock Market
What is the current price of Enlivex Therapeutics Ltd. - Ordinary Shares?
The current price of Enlivex Therapeutics Ltd. - Ordinary Shares is 0.9699
When was Enlivex Therapeutics Ltd. - Ordinary Shares last traded?
The last trade of Enlivex Therapeutics Ltd. - Ordinary Shares was at 11/28/25 01:00 PM ET
What is the market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares?
The market capitalization of Enlivex Therapeutics Ltd. - Ordinary Shares is 17.76M
How many shares of Enlivex Therapeutics Ltd. - Ordinary Shares are outstanding?
Enlivex Therapeutics Ltd. - Ordinary Shares has 18M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.